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Thirty-ﬁve percent of survivors were transplanted with related
donor cells, 25% with unrelated donor cells, and 40 percent had an
autologous transplant. Age at time of transplant ranged from 6
months to 69 years. Median age was 42.
The year of the survivor’s most recent transplant ranged from
1981 to 2006 with a median of 2002. Sixty-three of the respondents
had two or more transplants.
Issues of concer, rating by frequency with which they were cited,
are shown in Table 1.
Psychological health of the survivor (71%), monitoring long-
term complications (70%), chronic GVHD (74% allogeneic relat-
ed-donor transplant, 81% allogeneic unrelated-donor transplant)
and fatigue (66%) were the top issues cited by survivors. Other
major concerns were cognitive problems (49%), psychological
health of the family (47%), educating local doctors about long-
term follow-up care (43%), health insurance (42%), secondary
cancers (42%) and sexuality (41%).
Spouses expressed greater concern than survivors about ﬁnancial
problems (43% vs. 30%), psychological health of the family (59% vs.
47%), and caregiver burnout (44% vs. 29%). Survivors had greater
concern than spouses about cognitive problems (49% vs. 37%), sec-
ondary cancers (42% vs. 24%) and infertility (22% vs. 8%).
Spouses of survivors who were transplanted with unrelated donor
cells expressed concern more frequently than other spouses about
the psychological health of the survivor, fatigue, psychological
health of the family, and marital difﬁculties.
Ninety-one percent of respondents said they would be interested
in an educational forum to help them cope with survivorship issues.
The growing number of HSCT survivors requires a fresh look at
how to equip patients and families to live well post-transplant. The
results of this survey have been used to design of a one-day
Transplant Survivors Symposium, April 14, 2007 in Chicago IL.
Between 200 and 300 survivors and their families are expected to
attend. Symposium proceedings will be available to non-partici-
pants via the web, on CD, and in print.
Issues of Concern to HSCT Survivors and Spouses
Issue Survivors Spouses
Psychological Health of Survivor 71% 78%
Monitoring Long Term
Complications 70% 67%
Fatigue 66% 70%
Cognitive Problems 49% 37%
cGVHD 47% 49%
Psychological Health of Family 47% 59%
Educating Local Physicians About
Survivor Needs 43% 37%
Health Insurance 42% 44%
Secondary Cancers 42% 24%
Sexuality 41% 37%
Employment 36% 35%
Immunization 36% 30%
Life Insurance 33% 32%
Financial Problems 30% 43%
Caregiver Burnout 29% 44%
Dental Problems 26% 21%
Resume Relations w/ Family &
Friends 24% 17%
Infertility 22% 8%
Complementary/Alternative
Medicine 20% 13%
Marital Difficulties 20% 25%
Pain Control 19% 24%
Young Adult Issues 7% 5%
Sibling Needs 5% 3%
Behavioral Problems 2% 3%
Delayed Growth 1% 2%
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We previously demonstrated frequent genomic alterations
measured by microsatellite instability (MSI) in non-malignant
and malignant epithelial tissues of pts who underwent aHCT
(Blood 2006;107:3389-3396). Transplant survivors have a high
risk of developing secondary cancer, especially squamous cell
carcinomas. The p53 gene plays a pivotal role in maintaining
genome integrity and in the development of cancer. We hy-
pothesized that besides the alterations in microsatellite regions
also p53 mutations occur after aHCT and may play a role in
malignant transformation and development of secondary cancer.
Therefore, we performed mutation analysis of the p53 gene on
malignant cells isolated from parafﬁn-embedded tumor biopsies
from 4 pts that developed secondary epithelial malignancies
2-12 years post aHCT and on non-neoplastic buccal cells ob-
tained from 4 otherwise healthy pts 3-5 years following aHCT.
Buccal cells from 3 healthy individuals and HaCat cells with a
known p53 heterozygous mutation were used as negative and
positive controls, respectively. DNA extraction was followed by
proofread-PCR with speciﬁc primers for the exons 5-8. Each
PCR product was cloned in a pUC vector and transfected in
Escherischia coli chemocompetent cells. Sequence analysis was
performed on 8-12 clones per exon per patient. p53 mutations
were not found in the buccal cells of the aHCT healthy recip-
ients. p53 mutations were evident in 2 out of 4 tumor specimens.
One patient with a squamous cell carcinoma developed 2 years
post aHCT was found to harbour a single p53 mutation in exon
8. This p53 mutation was evident in 10 out of the 10 clones
tested, suggesting that 100% of the malignant cells were mu-
tated. In the second patient with an underlying malignancy of
the tongue, two different mutations (exons 5 and 8) in 50% of
the isolated cells were detected. Despite the small size of the
sample (4 pts), p53 mutations seem to occur frequently (50%) in
secondary malignancies after HCT. We didn
t ﬁnd p53 muta-
tions in nonmalignant epithelial cells of the oral cavity. How-
ever, given the low sensitivity of the applied methodology (de-
tection of a mutation if it affects more than 40% of the tissue
cells) we cannot exclude that indeed p53 mutations are already
present in a lower percentage of non-neoplastic cells before
overt malignant transformation occurs. Results regarding the
presence of p53 mutations in nonmalignant tissues affected with
chronic GvHD will be presented in the meeting.
LYMPHOMA/MULTIPLE MYELOMA
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LOW DOSE THALIDOMIDE MAINTENANCE IN MYELOMA PATIENTS
AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
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Autologous stem cell transplantation has become the gold
standard for treatment of patients with multiple myeloma under
the age of 65, and improves survival for these patients. It is
evident that all patients will progress after transplantation. At
this time it is not clear what is the best induction regimen prior
to high dose chemotherapy and ASCT. Thalidomide has been
proven to impact on plasma cell growth through multiple mech-
anisms. At our institution we used thalidomide (50-100 mg)
after ASCT as a maintenance program along with a bisphos-
phonate (Zometa or Aredia). We reviewed 68 myeloma patients
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